Clearside Biomedical Inc Quick Ratio (CLSD) starting from the third quarter 2025 to third quarter 2024, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket Company Name, Ticker, Customers, else..
 


• Quick Ratio
• Working Capital
• LT Debt to Equity
• Debt to Equity
• Leverage Ratio
• Tangible Leverage
• Interest Coverage
• Debt Coverage
• Work. Cap. Per Revenue
Clearside Biomedical Inc   (NASDAQ: CLSD)

Clearside Biomedical Inc 's Quick Ratio

CLSD's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


Regardless of the sequential decrease in Current Liabilities, during the third quarter 2025, Quick Ratio deteriorated to 2.85 below Clearside Biomedical Inc 's average Quick Ratio.

Within Major Pharmaceutical Preparations industry 194 other companies have achieved higher Quick Ratio than Clearside Biomedical Inc in third quarter 2025. While Quick Ratio total ranking in the third quarter 2025 has deteriorated compared to the prior quarter from 625 to 665.

Explain Quick Ratio?
How much Cash & cash equivalents CLSD´s has?
What are CLSD´s Current Liabilities?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

CLSD Quick Ratio (Sep 30 2025)
Q3		 (Jun 30 2025)
Q2		 (Mar 31 2025)
Q1		 (Dec 31 2024)
Q4		 (Sep 30 2024)
Q3
Y / Y Current Liabilities Change -54.29 % -51.56 % -17 % -31.48 % -4.62 %
Y / Y Cash & cash equivalent Change -71.17 % -68.07 % -61.45 % -30.77 % -18.09 %
Quick Ratio MRQ 2.85 3.52 2.94 4.53 4.52
CLSD's Total Ranking # 665 # 625 # 669 # 487 # 517
Seq. Current Liabilities Change -10.5 % -42.47 % 4.87 % -15.34 % -5.16 %
Seq. Cash & cash equivalent Change -27.46 % -31.2 % -31.93 % -15.14 % -19.65 %



Quick Ratio third quarter 2025 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 195
Healthcare Sector # 325
Overall Market # 665


Quick Ratio Statistics
High Average Low
19.44 5.74 1.56
(Sep 30 2016)   (Mar 31 2020)




Financial Statements
Clearside Biomedical Inc 's Current Liabilities $ 2 Millions Visit CLSD's Balance sheet
Clearside Biomedical Inc 's Cash & cash equivalent $ 7 Millions Visit CLSD's Balance sheet
Source of CLSD's Sales Visit CLSD's Sales by Geography


Cumulative Clearside Biomedical Inc 's Quick Ratio

CLSD's Quick Ratio for the trailling 12 Months

CLSD Quick Ratio

 (Sep 30 2025)
12 Months		 (Jun 30 2025)
12 Months		 (Mar 31 2025)
12 Months		 (Dec 31 2024)
12 Months		 (Sep 30 2024)
12 Months
Y / Y Current Liabilities TTM Growth -38.02 % -26.38 % -11.79 % -3.44 % 11.28 %
Y / Y Cash & cash equivalent TTM Growth -57.5 % -45.59 % -32.39 % -19.25 % -23.62 %
Quick Ratio TTM 3.53 3.93 4.38 5.23 5.15
Total Ranking TTM # 3056 # 2692 # 2459 # 3138 # 3126
Seq. Current Liabilities TTM Growth -16.73 % -14.35 % -4.58 % -8.92 % -1.1 %
Seq. Cash & cash equivalent TTM Growth -25.2 % -23.08 % -20.06 % -7.59 % -4.26 %

Quick ratio ranking by company, industry and sector >> Back to CLSD Financial Strength Comparisons >> Go to Compare CLSD Quick Ratio to its Competitors

On the trailing twelve months basis In spite of the year on year decrease in CLSD's Current Liabilities to $2.39 millions, cumulative Quick Ratio to 3.53 below the CLSD average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 409 other companies have achieved higher Quick Ratio than Clearside Biomedical Inc . While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the second quarter 2025 from 2692 to 3056.

Explain Quick Ratio?
How much Cash & cash equivalents CLSD´s has?
What are CLSD´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 410
Healthcare Sector # 844
Within the Market # 3056


trailing twelve months Quick Ratio Statistics
High Average Low
8.38 4.53 1.66
(Jun 30 2023)   (Dec 31 2020)




Companies with similar Quick Ratio in the quarter ending Sep 30 2025, within Major Pharmaceutical Preparations Industry Quick RatioSep 30 2025 MRQ Cash & cash equivalentSep 30 2025 MRQ Current Liabilities
Lipocine Inc   7.84 $ 15.131  Millions$ 1.931  Millions
Amarin Corp Plcuk  7.81 $ 286.888  Millions$ 36.712  Millions
Actinium Pharmaceuticals Inc  7.81 $ 53.391  Millions$ 6.834  Millions
Abcellera Biologics Inc   7.77 $ 412.513  Millions$ 53.117  Millions
Anixa Biosciences Inc   7.71 $ 15.174  Millions$ 1.967  Millions
Galmed Pharmaceuticals Ltd   7.71 $ 19.051  Millions$ 2.472  Millions
Coya Therapeutics Inc   7.67 $ 28.130  Millions$ 3.667  Millions
Zevra Therapeutics Inc   7.64 $ 199.509  Millions$ 26.112  Millions
Compass Pathways Plc  7.55 $ 186.316  Millions$ 24.692  Millions
Kiora Pharmaceuticals Inc   7.51 $ 19.375  Millions$ 2.580  Millions
Zentalis Pharmaceuticals Inc   7.49 $ 278.291  Millions$ 37.168  Millions
Galera Therapeutics Inc   7.48 $ 4.473  Millions$ 0.598  Millions
Savara Inc   7.42 $ 124.386  Millions$ 16.757  Millions
Ocular Therapeutix Inc   7.41 $ 344.772  Millions$ 46.532  Millions
Evommune Inc   7.30 $ 76.062  Millions$ 10.416  Millions
Annovis Bio Inc   7.24 $ 15.286  Millions$ 2.112  Millions
Forte Biosciences Inc   7.19 $ 93.414  Millions$ 12.992  Millions
Rocket Pharmaceuticals Inc   7.15 $ 222.758  Millions$ 31.170  Millions
Chemomab Therapeutics Ltd   7.01 $ 10.366  Millions$ 1.478  Millions
Ataibeckley Inc   6.93 $ 114.606  Millions$ 16.544  Millions
Anaptysbio Inc   6.90 $ 248.956  Millions$ 36.064  Millions
Barinthus Biotherapeutics Plc  6.88 $ 74.272  Millions$ 10.798  Millions
Kalvista Pharmaceuticals Inc   6.86 $ 309.158  Millions$ 45.069  Millions
Revelation Biosciences Inc   6.85 $ 12.708  Millions$ 1.854  Millions
Kezar Life Sciences Inc   6.74 $ 90.216  Millions$ 13.376  Millions
Inmed Pharmaceuticals Inc  6.72 $ 9.443  Millions$ 1.404  Millions
Hepion Pharmaceuticals Inc   6.68 $ 2.321  Millions$ 0.347  Millions
Lexicon Pharmaceuticals Inc   6.66 $ 115.950  Millions$ 17.417  Millions
Talphera Inc   6.63 $ 21.289  Millions$ 3.212  Millions
Crescent Biopharma Inc   6.56 $ 133.265  Millions$ 20.304  Millions

Date modified: 2026-09-18T13:11:06+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.